Recent events
Recent events tied to this brand in public sources.
Back to profile11 entries
2026
Innovent Biologics and Takeda announce global strategic partnership
Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to develop potential first-in-class targeted innovative drugs. Upfront and milestone payments total more than US$1 billion.
2022
Innovent and Lilly deepen oncology partnership in China
Innovent and Lilly announced an agreement deepening their oncology partnership. Innovent will receive exclusive commercialization rights in mainland China after approval for Cyramza and Retsevmo, and priority negotiation rights for future commercialization of Pirtobrutinib in mainland China.
2021
Innovent and Ascentage announce strategic collaboration
Innovent Biologics and Ascentage Pharma announced a strategic collaboration covering joint commercialization in China of HQP1351 after approval, exploration of clinical co-development for several medicines, and an equity investment in Ascentage Pharma.
2020
NMPA approves SULINNO in China
China's National Medical Products Administration approved Innovent Biologics' adalimumab injection SULINNO for marketing to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
2020
Innovent and Lilly expand sintilimab collaboration globally
Innovent Biologics and Eli Lilly announced an expansion of their strategic collaboration on sintilimab: Innovent granted Lilly an exclusive license for the drug outside China, and Lilly will work to bring it to North America, Europe and other regions. The agreement is subject to customary closing conditions, including U.S. antitrust approval.
2020
Innovent Biologics and Geneseeq formed a companion-diagnostics partnership
Innovent Biologics and Beijing Geneseeq Technology entered a strategic collaboration to jointly develop and commercialize companion diagnostic reagents in China for pemigatinib, for detecting FGFR2 gene fusion or rearrangement mutations in patients with cholangiocarcinoma.
2020
Innovent and Roche enter strategic collaboration
Innovent Biologics, through its wholly owned subsidiary Innovent Biologics (HK) Limited, entered a strategic collaboration with Roche focused on research, clinical development and commercialization of bispecific antibody and cell therapy products.
2020
Innovent Biologics and MD Anderson announce strategic collaboration on sintilimab
Innovent Biologics and MD Anderson Cancer Center announced a strategic collaboration to jointly develop sintilimab in the United States for multiple rare cancers. The partners will jointly bear development costs, which may include multiple clinical studies conducted by MD Anderson.
2020
Innovent and Alector partner on AL008 in China
Innovent Biologics and Alector announced a collaboration under which Innovent received rights to develop and commercialize Alector's AL008 antibody in China, including Hong Kong, Macao, and Taiwan. Innovent will lead development and commercialization in China, including manufacturing; Alector will lead development outside China.
2020
Innovent and Alector announce AL008 collaboration in China
Innovent Biologics and Alector announced a collaboration under which Innovent received rights to develop and commercialize Alector’s anti-SIRP-alpha antibody AL008 in China, including Hong Kong, Macau and Taiwan. Innovent will lead development and commercialization in China, including product manufacturing, while Alector will lead development outside China.
2020
Innovent and Sirnaomics announce clinical research partnership
Innovent Biologics and Sirnaomics announced a strategic collaboration to conduct clinical research in the United States combining Innovent’s sintilimab with Sirnaomics’ RNAi candidate STP705 for tumors including hepatocellular carcinoma and cholangiocarcinoma.